Zentalis(US:ZNTL)2025-05-14 20:09Clinical Trial Updates - First patient dosed in Part 2a of the DENALI clinical trial for azenosertib in Cyclin E1+ platinum-resistant ovarian cancer (PROC) with a target enrollment of approximately 30 patients at two dose levels [4] - Topline data from DENALI Part 2 is anticipated by year-end 2026, which could support accelerated approval pending FDA feedback [2] - The objective response rate (ORR) for azenosertib in patients with Cyclin E1+ PROC was reported at 34.9% with a median duration of response of 6.3 months as of January 13, 2025 [4] Financial Performance - Cash, cash equivalents, and marketable securities as of March 31, 2025, totaled $332.5 million, sufficient to fund operations into late 2027 [8] - Research and development expenses decreased to $27.2 million for Q1 2025 from $49.6 million in Q1 2024, a reduction of $22.4 million [8] - General and administrative expenses for Q1 2025 were $10.6 million, down from $15.7 million in Q1 2024, reflecting a decrease of $5.1 million [8] - Total operating expenses for Q1 2025 were $45.6 million, compared to $65.3 million in Q1 2024, including $7.8 million in non-recurring restructuring expenses [8] - Net loss attributable to Zentalis for Q1 2025 was $48.3 million, compared to a net income of $10.1 million in Q1 2024 [15] - Total assets as of March 31, 2025, were $384.0 million, down from $430.3 million as of December 31, 2024 [17] - Total liabilities decreased to $88.6 million as of March 31, 2025, from $93.2 million as of December 31, 2024 [17]